-

Zoetis to Participate in the 39th Annual J.P. Morgan Healthcare Conference

PARSIPPANY, N.J.--(BUSINESS WIRE)--Zoetis Inc. (NYSE:ZTS) will participate in the 39th Annual J.P. Morgan Healthcare Conference on Monday, Jan. 11, 2021. Kristin Peck, Chief Executive Officer, will represent the company and respond to questions from analysts. She is scheduled to present at 10:00 a.m. ET.

Investors and other interested parties will be able to access a live audio webcast of the virtual presentation by visiting http://investor.zoetis.com/events-presentations. A replay of the presentation will also be available on the Zoetis website at the conclusion of the event.

About Zoetis

Zoetis is the leading animal health company, dedicated to supporting its customers and their businesses. Building on more than 65 years of experience in animal health, Zoetis discovers, develops, manufactures and commercializes medicines, vaccines and diagnostic products, which are complemented by biodevices, genetic tests and precision livestock farming. Zoetis serves veterinarians, livestock producers and people who raise and care for farm and companion animals with sales of its products in more than 100 countries. In 2019, the company generated annual revenue of $6.3 billion with approximately 10,600 employees. For more information, visit www.zoetis.com.

ZTS-COR
ZTS-IR

Contacts

Media Contacts:
Bill Price
1-973-443-2742 (o)
william.price@zoetis.com

Kristen Seely
1-973-443-2777 (o)
kristen.seely@zoetis.com

Investor Contacts:
Steve Frank
1-973-822-7141 (o)
steve.frank@zoetis.com

Keith Gaub
1-973-822-7154 (o)
keith.gaub@zoetis.com

Zoetis Inc.

NYSE:ZTS

Release Summary
Zoetis to present at the 39th Annual J.P. Morgan Healthcare Conference on January 11, 2021.
Release Versions
$Cashtags

Contacts

Media Contacts:
Bill Price
1-973-443-2742 (o)
william.price@zoetis.com

Kristen Seely
1-973-443-2777 (o)
kristen.seely@zoetis.com

Investor Contacts:
Steve Frank
1-973-822-7141 (o)
steve.frank@zoetis.com

Keith Gaub
1-973-822-7154 (o)
keith.gaub@zoetis.com

Social Media Profiles
More News From Zoetis Inc.

Zoetis Receives USDA License for Cytopoint Plus™: The First and Only Long-Acting Monoclonal Antibody Providing 75 Days of Allergic Itch Relief in Dogs with Allergic Dermatitis

PARSIPPANY, N.J.--(BUSINESS WIRE)--Cytopoint Plus is the first and only USDA-licensed next-generation mAb that provides 75 days of allergic itch relief in a single injection....

Zoetis to Participate in the Jefferies Global Healthcare Conference in London

PARSIPPANY, N.J.--(BUSINESS WIRE)--Zoetis Inc. (NYSE:ZTS) today announced that Jay Saccaro, EVP, Chief Financial Officer and Chief Operating Officer, will participate in a fireside chat at the Jefferies Global Healthcare Conference in London on Monday, November 16, 2026 at 2 p.m. GMT. Interested parties can access the live webcast of the presentation by visiting https://investor.zoetis.com/events-presentations. A replay will also be available on the Zoetis website at the conclusion of the event...

Zoetis Announces Third Quarter 2026 Results; Highlights Progress Advancing Innovation Across Diversified Portfolio and Narrows Full Year 2026 Revenue Guidance, Raises Full Year 2026 Adjusted EPS Guidance

PARSIPPANY, N.J.--(BUSINESS WIRE)--Zoetis Inc. (NYSE:ZTS), the world's leading animal health company, today reported its financial results for the third quarter of 2026. "Our third-quarter performance was in line with our expectations. Continued pressure in Companion Animal was partially offset by growth in Livestock and Diagnostics, reflecting the breadth of our portfolio," said Kristin Peck, Chief Executive Officer of Zoetis. "We remain focused on defending our position and directing our reso...
Back to Newsroom